U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07145268) titled 'Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy' on Aug. 20.
Brief Summary: This study aims to investigate the possible safety and efficacy of Zinc sulphate as antifibrotic agent in chronic HBV patient receiving antiviral therapy.
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Liver Fibroses
HBV (Hepatitis B Virus)
Intervention:
DRUG: Entecavir (ETV)
Standard antiviral therapy with Entecavir 0.5 mg orally once daily for 6 months."(control group)
DRUG: Zinc (zinc sulphate)
Zinc sulfate 220 mg orally once daily (50 mg elemental zinc) in addition to Entecavir 0.5 mg, for 6 month...